Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression Background <p>Prostate cancer (PCa) is widely recognized as an immunologically "cold" tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been identified as a marker of highly cytotoxic CD8<sup>+</sup> T cells in other malignancies, its identity, regulatory mechanisms, and clinical significance in PCa remain poorly… Journal for ImmunoTherapy of Cancer March 12, 2026 Original source
Complement system in cancer: friend or foe of immunotherapy <p>The complement system, a key component of the immune response, plays a dual role in cancer, influencing both tumor suppression and progression. Its three activation pathways (classical, alternative, and lectin) initiate immune processes, including opsonization and cell lysis. Within the tumor microenvironment, however, complement activation can paradoxically support immune-mediated tumor control or contribute to immune evasion and tumor growth. Therapeutic… Journal for ImmunoTherapy of Cancer March 12, 2026 Original source
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609) Background <p>Mixed response, where different lesions within the same patient show discordant responses to treatment, remains poorly understood. To better understand the complex effects of mixed response on patient survival, we devised three different definitions of mixed response. This retrospective analysis provides the first evaluation of the association between mixed response and survival outcomes in patients with rare cancers treated… Journal for ImmunoTherapy of Cancer March 12, 2026 Original source
CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis Background <p>Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has transformed the treatment of hematologic malignancies. The costimulatory domain (CSD) of CAR constructs plays a crucial role in determining T cell metabolism, persistence, and antitumor function. We previously developed a novel CSD combining CD79A and CD40, which conferred superior proliferation and antitumor efficacy compared with CD28-based or 4-1BB-based CAR-T cells.… Journal for ImmunoTherapy of Cancer March 12, 2026 Original source
How Long Does Radiation Stay in Your Body After Treatment? <p>Along with surgery, chemotherapy and radiation therapy have long been a mainstay of cancer treatment. It uses high-energy waves or particles such as X-rays, electrons, protons, or alpha particles, to destroy or damage tumor cells. Radiation creates small breaks within the DNA of cancer cells, preventing the cells from growing and dividing, and often causing ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/03/how-long-does-radiation-stay-in-your-body-after-treatment/" title="How… Dana-Farber Cancer Institute March 11, 2026 Original source
Targeting the Sialic acid/Siglec axis: opportunities and challenges in colorectal cancer immunotherapy Journal for ImmunoTherapy of Cancer March 10, 2026 Original source
Clinical application prospects of Nectin-4 in pan-cancer: an analysis based on the Trialtrove database <p>This research analyzes the global landscape of clinical trials focusing on therapies targeting the Nectin cell adhesion molecule 4 (Nectin-4) across various malignancies, using data from the Trialtrove database. Analysis of 136 interventional trials reveals a rapidly expanding field dominated by antibody-drug conjugates, particularly in urothelial carcinoma, with significant activity in combination regimens and diverse therapeutic modalities under exploration. These… Journal for ImmunoTherapy of Cancer March 10, 2026 Original source
Clinical trial landscape of CAR-based cell therapy for gastrointestinal malignancies <p>Gastrointestinal malignancies (GIM) impose a substantial global health burden, accounting for approximately 33% of cancer-related mortality worldwide. Although chimeric antigen receptor (CAR)-based cell therapy has achieved remarkable success in hematological malignancies, its application in solid tumors, particularly GIM, remains in its nascent stages. This comprehensive landscape analysis systematically examined the clinical trial ecosystem of CAR-based cell therapy for GIM by… Journal for ImmunoTherapy of Cancer March 10, 2026 Original source
AGPAT3 reshapes tumor cell vulnerability to IFN{gamma}-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling Background <p>Ferroptosis plays a critical role in immune regulation and tumor microenvironment remodeling. However, its therapeutic potential in enhancing immune checkpoint inhibitor (ICI) efficacy remains incompletely understood and warrants further investigation.</p> Methods <p>To investigate the potential of ferroptosis in improving ICI response, we constructed a machine learning-based predictive model using ferroptosis-related genes and analyzed large-scale single-cell RNA sequencing datasets. Mechanistic… Journal for ImmunoTherapy of Cancer March 10, 2026 Original source
What’s the Difference Between Outpatient and Inpatient CAR T-Cell Therapy? <p>CAR T-cell therapy is a newer form of immunotherapy that can treat some types of blood cancers, such as lymphoma, multiple myeloma, and leukemia.  Patients can be treated with this therapy as an inpatient or outpatient, depending on their case and specific needs.   “Historically, we were giving these therapies in the hospital, but what we’ve learned over the last few years is that outpatient therapy is very safe ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/03/car-t-cell-therapy-inpatient-vs-outpatient/" title="What’s… Dana-Farber Cancer Institute March 10, 2026 Original source
Hyaluronic acid-CD44 signaling defines therapeutic resistance and immunosuppressive microenvironment in peritoneal metastasis of gastric cancer Background <p>Peritoneal metastasis (PM) is one of the most challenging clinical problems in gastric cancer (GC), largely due to its high recurrence rate and poor response to current therapies. Increasing evidence indicates that remodeling of the extracellular matrix (ECM) plays an important role in therapeutic failure. However, how specific stromal–immune interactions contribute to PM heterogeneity and immunotherapy resistance remains unclear.… Journal for ImmunoTherapy of Cancer March 9, 2026 Original source
Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy Background <p>Antigen escape is one of the leading causes of relapse following chimeric antigen receptor (CAR)-T therapy, particularly in multiple myeloma. A critical gap persists in understanding the tumor-intrinsic pathways that trigger antigen loss, insight essential for devising strategies to resensitize tumors to immune attack. We identify a previously uncharacterized post-translational mechanism centered on the metabolic enzyme ribonucleotide reductase subunit… Journal for ImmunoTherapy of Cancer March 9, 2026 Original source
Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy Background <p>Programmed death-ligand 1 (PD-L1)-targeted radiopharmaceutical therapy (RPT) combined with immune checkpoint blockade (ICB) represents a promising combinatorial treatment because of the "magic" bystander and abscopal effects of RPT. However, the overall efficacy of this combinatorial approach is often constrained by limited tumor retention and insufficient accumulation of existing radiopharmaceuticals. D-peptides, with their superior metabolic stability, offer a promising modality… Journal for ImmunoTherapy of Cancer March 9, 2026 Original source
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers Background <p>The orally available toll-like receptor 7 (TLR7) agonist prodrug RO7119929 is converted to active drug predominantly in the liver, where it is hypothesized to reprogram the local immune microenvironment. We aimed to explore the safety, pharmacokinetics (PK), and preliminary antitumor activity and obtain the proof-of-mechanism for RO7119929 in patients with liver cancer.</p> Methods <p>RO7119929 was investigated in mouse tumors… Journal for ImmunoTherapy of Cancer March 9, 2026 Original source
Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes <p>Prostate Cancer and Prostatic Diseases, Published online: 06 March 2026; <a href="https://www.nature.com/articles/s41391-026-01095-7">doi:10.1038/s41391-026-01095-7</a></p>Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes Prostate Cancer Journal March 6, 2026 Original source
Re-routing IgE for cancer therapy <p>Nature Reviews Cancer, Published online: 06 March 2026; <a href="https://www.nature.com/articles/s41568-026-00917-z">doi:10.1038/s41568-026-00917-z</a></p>In a study published in Cell, Xu et al. show that mast cells engineered with tumour-antigen specific antibodies and loaded with an oncolytic virus can be activated by antigen encounter to drive targeted tumour cell killing and amplify local anti-tumour immunity. Nature Reviews Cancer March 6, 2026 Original source
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma Background <p>The gut microbiota plays a critical role in regulating immune homeostasis and modulating responses to cancer immunotherapies. However, the impact of antibiotic-induced dysbiosis in patients with multiple myeloma (MM) treated with bispecific antibodies (BsAbs) remains unexplored. This multicenter, international study investigated whether antibiotic exposure prior to BsAb initiation alters the gut microbiome and affects clinical outcomes in patients with… Journal for ImmunoTherapy of Cancer March 6, 2026 Original source
Integrating interferon gamma receptor pathways, antigenicity, and immune contexture as predictors of immunotherapeutic strategies for mucosal melanomas Background <p>Mucosal melanomas (MM) arise from mucosal melanocytes at various anatomical sites. These tumors are rare, highly aggressive, and often associated with poor outcomes. Current treatments, including immune checkpoint inhibitors, show limited efficacy in advanced disease. Compared with cutaneous melanomas, there is a lack of data on the immunogenicity and interferon (IFN)- sensitivity of MM. In this study, we examined… Journal for ImmunoTherapy of Cancer March 6, 2026 Original source
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study Background <p>Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.</p> Objectives <p>To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).</p>… Journal for ImmunoTherapy of Cancer March 5, 2026 Original source
Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis Background <p>Immune-related hepatitis (ir-hepatitis) ranks among the most frequent adverse events of immune checkpoint inhibitors (ICIs). Limited knowledge exists regarding the incidence, characteristics, and treatment of patients having an inadequate response to initial therapy with steroids. Characterizing ir-hepatitis phenotypes and treatment responses can provide valuable insights for guiding treatment decisions and prognosis.</p> Methods <p>This is a prospective study including patients… Journal for ImmunoTherapy of Cancer March 5, 2026 Original source